Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

    NEXT STORY
    Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
    PREV STORY
    10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting

    Additional Analyses Provide Insight into Treatment Effect of VB-111 TEL AVIV, Israel, Nov. 16, ...

    author_avatar
    NASDAQ Market News

    ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022

    - OBE022 is ObsEva's potential first-in-class, oral and selective PGF2alpha receptor antagonist for the ...

    author_avatar
    NASDAQ Market News

    MDxHealth Appoints Global Commercial Team for SelectMDx

    IRVINE, Calif. and HERSTAL, Belgium, March 9, 2016 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: ...

    author_avatar
    NASDAQ Market News